Format

Send to

Choose Destination
F1000Res. 2018 Sep 21;7. pii: F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1. eCollection 2018.

Recent trends in the management of advanced prostate cancer.

Author information

1
Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.
2
Department of Urology, University of Oklahoma College of Medicine and Stephenson Cancer Center, Oklahoma City, OK, USA.

Abstract

Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or abiraterone acetate to ADT results in significant survival advantage as compared with ADT alone. Furthermore, in non-metastatic castration-resistant prostate cancer (M0 CRPC), two second-generation anti-androgens, apalutamide and enzalutamide, when used in combination with ADT, have demonstrated a significant benefit in metastasis-free survival. Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.

KEYWORDS:

castration resistant prostate cancer; chemohormonal therapy; hormone sensitive metastatic prostate cancer; prostate cancer

PMID:
30345007
PMCID:
PMC6173112
DOI:
10.12688/f1000research.15382.1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center